COMPARISON
Melanotan II vs GLOW: Same Category, Different Evidence
One compound with direct human data and a documented risk profile. One blend built from well-studied parts that has never itself been tested.
The short version
Melanotan II and GLOW both get filed under 'skin peptides,' but they are not close cousins. Melanotan II is a single molecule that has been dosed in actual human pilot studies — it darkens skin, suppresses appetite, and raises libido, and it has a real, published record of serious side effects up to and including melanoma. GLOW is three separate peptides mixed together for skin texture and healing. Each of those three has its own research. None of them has been studied as the combined product a buyer actually injects.
The practical difference: with Melanotan II, the risks below come from studies and case reports of the exact compound. With GLOW, the risks are inferred from its individual parts, because the blend itself has never been tested. Neither gap makes one safer than the other — it just means the uncertainty sits in a different place.
Mechanism, side by side
| Melanotan II | GLOW | |
|---|---|---|
| What it is | Single synthetic peptide, cyclic alpha-MSH analog | Combination of GHK-Cu, BPC-157, and TB-500 |
| Primary receptor/pathway | Melanocortin receptors MC1R-MC5R | GHK-Cu: copper/matrix signaling. BPC-157: VEGFR2-Akt-eNOS. TB-500: actin-binding cell migration |
| Intended effect | Skin pigmentation without UV; secondary appetite and libido effects | Skin texture, collagen support, tissue repair |
| Route | Subcutaneous injection | Subcutaneous injection |
| Standardized formula | Yes — one defined sequence | No — ratios vary by supplier |
Melanotan II acts on one receptor family with a single, well-defined mechanism [4]. GLOW stacks three unrelated mechanisms into one vial on the theory that they reinforce each other for skin and repair — a plausible idea that has not been tested as a combination [8].
Evidence maturity
Melanotan II has direct controlled human data, though all of it is small and old by clinical-trial standards. A 10-man crossover study established its erectile effect [5]; a 3-man pilot established measurable pigmentation without UV exposure [6]. No Phase II or III trial exists for Melanotan II, and none is planned — the compound was abandoned for further clinical development decades ago, though its lineage produced two peptides that were separately approved for other indications [4].
GLOW's evidence is stronger at the component level and weaker at the product level. GHK-Cu has the deepest human research of the three, including topical skin-improvement studies [11][12]. BPC-157 has only three small human pilot studies and is explicitly labeled investigational by its own reviewers [9]. TB-500 (as the synthetic fragment) has the least direct human data of all three. A 2026 review naming all three together is candid that human safety data for this class of compounds remain scarce [8]. Put simply: Melanotan II's evidence gap is in trial size. GLOW's evidence gap is that the product itself was never studied.
Reported effects, in the community
Anecdotal, not clinical evidence, for both compounds — none of the following comes with a verified dose.
Melanotan II's most consistently reported effects are pigmentation (the reason people use it), reduced appetite, increased libido, and nausea. Its most concerning consistently reported signal is darkening of existing moles and the appearance of new ones — directly reflected in the published melanoma case-report literature.
GLOW's most consistently reported effect is an overall brighter, smoother-looking complexion, credited mainly to the GHK-Cu component, alongside faster-looking wound and tissue recovery credited to BPC-157 and TB-500. Its most consistently reported downside is injection-site sting from the copper-peptide component itself, not a systemic safety signal.
Safety record, in full
Melanotan II carries the more serious documented safety record of the two: case-reported melanoma and eruptive moles, renal infarction and rhabdomyolysis [3], priapism, and posterior reversible encephalopathy syndrome. These are not theoretical — they are published case reports of the compound itself. It is also unregulated as sold, meaning purity and dosing accuracy cannot be verified.
GLOW's safety picture is different in kind. Its individual components carry theoretical, mechanism-based cautions rather than case-reported harms specific to the blend: angiogenesis and cancer risk from BPC-157 and TB-500, copper-accumulation risk from GHK-Cu, and anti-doping exposure from TB-500. GLOW is also unregulated as sold, and — unlike Melanotan II — the combination product has literally never been dosed in a human trial, so its combined safety profile is unknown rather than merely under-studied.
Neither compound is FDA-approved. Neither should be treated as a cosmetic or a treatment. Read the full Melanotan II safety section and the full GLOW safety section before drawing any conclusion from this summary alone.